banner
Not an actual patient

At Astellas Gene Therapies, our mission is to develop genetic medicines with the potential to transform patients’ lives. Today, we are boldly forging the future of gene therapy by conducting investigational research in
X-Linked Myotubular Myopathy (XLMTM), Pompe disease, Friedreich ataxia (FA), and
Myotonic Dystrophy Type 1. As part of our commitment to the patients and families we serve, we are constantly seeking to deepen our understanding of the lived experience of those affected by genetic disorders in order to provide access to information and resources that could be helpful to the communities we support.

Our Patient Partnerships Team is dedicated to bringing patient expertise into all aspects of our development programs. Our priority is to weave patient and caregiver perspectives into the fabric of all that we do on a day-to-day basis. And we advocate for patients and families with the commitment, dedication and passion that it takes to be sure that our whole organization is doing what is best for patients.

split img

 

xlmtm image

Not an actual patient

XLMTM

X-Linked Myotubular Myopathy (XLMTM) is a serious rare, genetic condition that affects skeletal muscles leading to severe muscle weakness (hypotonia) and profound respiratory distress, often requiring invasive ventilation support. XLMTM is a monogenic disorder, caused by pathogenic variants in the MTM1 gene, resulting in absent or dysfunctional myotubularin protein.

Learn More >>

Pompe Disease image

Maddie

Pompe disease

Pompe disease is a rare, inherited disorder characterized by progressive muscle weakness and respiratory impairment. It is caused by acid alpha-glucosidase (GAA) enzyme deficiency resulting from variants in the GAA gene. Absence or deficiency of GAA results in accumulation of glycogen in the lysosomes of all cells in the body.

Learn More >>

Friedreich ataxia (FA) image

Sean

Friedreich ataxia (FA)

Friedreich ataxia (FA) is a rare, multisystem autosomal recessive disease, which most often presents in childhood or in young adulthood. Clinical characteristics include progressive ataxia (a loss of muscle control and balance), spasticity (extreme muscle tightness and prolonged contractions), and cardiomyopathy.

Learn More >>

Myotonic Dystrophy Type 1 (DM1) image

Jonathan, Matthew, and Daniela

Myotonic Dystrophy Type 1

Myotonic dystrophy type 1 (DM1) is a rare, genetic, neuromuscular disease that affects multiple organ systems with symptoms ranging from myotonia and muscle weakness to cardiac and respiratory dysfunction, excessive sleepiness, and intellectual disability.

Learn More >>

split img

 

If you are interested to learn more about the drug development process and clinical trials for gene therapy treatments, please see the "Our Pipeline" page.

 

split img
Check us out on Social Icon

 Check us out on Social

At Astellas Gene Therapies, we prioritize patients and those important to them.
See below for our latest communications

split img

 

sign image

Please contact the Astellas Gene Therapies Patient and Engagement Team:

[email protected]

 

split img